This trial will test if XEN1101 is an effective and safe treatment for focal epilepsy in adults. The trial will be double-blind, meaning neither the patients nor the researchers will know who is receiving the real treatment or the placebo. There will also be an optional open-label extension, meaning that at the end of the trial, patients who wish to can receive the real treatment.
XEN1101 is approved by the FDA to treat Gelastic Epilepsy, a condition characterized by brief episodes of laughter. XEN1101 was previously approved by the FDA for a different condition.